Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, open-label, randomized, three-arm, dose-escalation exploratory
pilot clinical trial involving HIV-1 infected participants treated with suppressive
combination antiretroviral combination therapy (cART). The study will test whether combined
treatment with the histone deacetylase inhibitor panobinostat and the immunomodulatory
cytokine Interferon-alpha2a can reduce the residual reservoir of HIV-1 infected cells that
persist during treatment with currently available antiretroviral drugs.